Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF
Authors:
Open Access
- 4 August 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 22 (11) , 2147-2156
Abstract
Aim: To estimate the cost-effectiveness of dapagliflozin added to standard therapy, vs. standard therapy only, in patients with heart failure (HF) with reduced ejection fraction (HFrEF), from the perspective of UK, German, and Spanish payers. Methods and results: A lifetime Markov model was built to estimate outcomes in patients with HFrEF. Health states were defined by Kansas City Cardiomyopathy Questionnaire total symptom score, type 2 diabetes and worsening HF events. The incidence of worsening HF and all-cause mortality was estimated using negative binomial regression models and parametric survival analysis, respectively. Direct healthcare costs (2019 British pounds/Euro) and patient-reported outcomes (EQ-5D) were sourced from the existing literature and the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF), respectively; the median duration of follow-up in DAPA-HF was 18.2 months (range: 0–27.8). Future costs and effects were discounted at 3.0% for the Spanish and German analyses and 3.5% for the UK analysis. In the UK setting, treatment with dapagliflozin was estimated to increase life-years and quality-adjusted life-years (QALYs) from 5.62 to 6.20 (+0.58) and 4.13 to 4.61 (+0.48), respectively, and reduce lifetime hospitalizations for HF (925 and 820 events per 1000 patients for placebo and dapagliflozin, respectively). Similar results were obtained for Germany and Spain. The incremental cost-effectiveness ratios were £5822, €5379 and €9406/QALY in the UK, Germany and Spain, respectively. In probabilistic sensitivity analyses, more than 90% of simulations were cost-effective at a willingness-to-pay threshold of £20 000/QALY in UK and €20 000/QALY in Germany and Spain. Conclusion: Dapagliflozin is likely to be a cost-effective treatment for HFrEF in the UK, German and Spanish healthcare systems.Keywords
This publication has 43 references indexed in Scilit:
- COST-EFFECTIVENESS ANALYSIS OF CARDIAC RESYNCHRONIZATION THERAPY IN PATIENTS WITH NYHA I AND NYHA II HEART FAILURE IN SPAINInternational Journal of Technology Assessment in Health Care, 2013
- Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level DataMedical Decision Making, 2013
- Rehospitalization for Heart FailureJACC, 2013
- Rehospitalization for Heart FailureCirculation, 2012
- What are the costs of heart failure?EP Europace, 2011
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)European Heart Journal, 2008
- Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failureHeart, 2006
- Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetesCurrent Medical Research and Opinion, 2006
- Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)Medical Decision Making, 2002
- Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)Medical Decision Making, 2002